Bayer: prostate cancer drug meets goal in late-stage study

(CercleFinance.com) - German drug and chemical giant Bayer said its experimental cancer drug Darolutamide, in a Phase III clinical study, met its primary endpoint in patients with non-metastatic castration-resistant prostate cancer.


Darolutamide - which is jointly developed with Finland's Orion - significantly extended metastasis-free survival compared to placebo, the company said.

Bayer has been granted a "fast track" designation by the US Food and Drug Administration (FDA) for Darolutamide in men with non-metastatic castration-resistant prostate cancer, Bayer said.

Copyright (c) 2018 CercleFinance.com. All rights reserved.